Drug intelligence / Profile preview

JNJ-88545223

Development stage: Phase 2
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-88545223 is an investigational, orally bioavailable small molecule inhibitor of interleukin-17A (IL-17A) being developed by Johnson & Johnson (formerly Janssen Research & Development). It is designed to treat chronic immune-mediated inflammatory diseases by blocking the IL-17A signaling pathway, which is a critical driver of inflammation in the skin and joints. Currently in Phase 2 clinical development, JNJ-88545223 is being evaluated for its efficacy and safety in patients with active psoriatic arthritis and plaque psoriasis. As an oral therapy, it aims to provide a more convenient alternative to the injectable monoclonal antibodies that currently dominate the IL-17 inhibitor market.

Targets

IL-17A (Interleukin-17A)IL17F (Interleukin 17F)IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on JNJ-88545223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-88545223.

Explore the full profile